Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Market Cap	$137.24M	P/E Ratio	N/A
52W High	$1.94	52W Low	$0.66
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	9.9%	52W Position	44.5%
Overall Score	51	Value Score	60
Quality Score	36	Technical Score	58

EPS Current Est	$-1.15	EPS Next Est	$-1.16
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FATE	$1.23	+3.36%	1.67M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FATE	$1.23	+3.4%	1.67M
3
4
5
6

FATE

FATE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Fate Therapeutics Inc. Data in Excel

Get Fate Therapeutics Inc. Data in Excel